Science

Pipeline

 

Inhaled AAT

  •  
  • Phase I
  • Phase II
  • Phase III
EU Phase 2/3 (completed) MAA withdrawn (June 2017)
US Phase 2 (completed), EMA accepted new Ph3 design, FDA acceptance of path forward

Therapeutic Area: AAT Deficiency

EMA accept new Ph3 design, FDA acceptance of Inhaled AAT program path forward.
May seek partner upon IND/CTA approval.

G1-AAT (IV)

  •  
  • Phase I
  • Phase II
  • Phase III
Phase 2 (ongoing)

Therapeutic Area: Graft vs Host Disease (GvHD)

Phase 1/2 (completed)
Phase 2 in collaboration with MAGIC 3

L1-AAT (IV)

  •  
  • Phase I
  • Phase II
  • Phase III
Phase 2 (ongoing)

Therapeutic Area: Lung Transplant

In collaboration with Takeda/Shire

D1-AAT (IV)

  •  
  • Phase I
  • Phase II
  • Phase III
Phase 2 (completed)

Therapeutic Area: Type 1 Diabetes

Seeking partner for further development.

Recombinant AAT

  •  
  • Phase I
  • Phase II
  • Phase III
Early Development

Therapeutic Area: AAT Deficiency

Early stage development.

AAT (liquid)

  •  
  • Phase I
  • Phase II
  • Phase III
Ex-Vivo study

Therapeutic Area: Organ preservation

In collaboration with Massachusetts General Hospital.

Kamada is at the forefront of clinical research for plasma-derived proteins and additional therapeutic indications for Alpha-1 Antitrypsin (AAT).

The company has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency, and in addition, its intravenous AAT is in development for other indications, such as GvHD, prevention of lung transplant rejection and type-1 diabetes.